Mainardi Andrea, Carminati Francesca, Ugolini Giovanni Stefano, Occhetta Paola, Isu Giuseppe, Robles Diaz Diana, Reid Gregory, Visone Roberta, Rasponi Marco, Marsano Anna
Departments of Biomedicine and Surgery, University Basel and University Hospital Basel, Hebelstrasse 20, CH-4031 Basel, Switzerland.
Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milano, Italy.
Lab Chip. 2021 Oct 26;21(21):4177-4195. doi: 10.1039/d1lc00092f.
Cardiac fibrosis is a maladaptive remodeling of the myocardium hallmarked by contraction impairment and excessive extracellular matrix deposition (ECM). The disease progression, nevertheless, remains poorly understood and present treatments are not capable of controlling the scarring process. This is partly due to the absence of physiologically relevant, easily operable, and low-cost models, which are of the utmost importance to uncover pathological mechanisms and highlight possible targets for anti-fibrotic therapies. In classic models, fibrotic features are usually obtained using substrates with scar mimicking stiffness and/or supplementation of morphogens such as transforming growth factor β1 (TGF-β1). Qualities such as the interplay between activated fibroblasts (FBs) and cardiomyocytes (CMs), or the mechanically active, three-dimensional (3D) environment, are, however, neglected or obtained at the expense of the number of experimental replicates achievable. To overcome these shortcomings, we engineered a micro-physiological system (MPS) where multiple 3D cardiac micro-tissues can be subjected to cyclical stretching simultaneously. Up to six different biologically independent samples are incorporated in a single device, increasing the experimental throughput and paving the way for higher yielding drug screening campaigns. The newly developed MPS was used to co-culture different ratios of neonatal rat CMs and FBs, investigating the role of CMs in the modulation of fibrosis traits, without the addition of morphogens, and in soft substrates. The expression of contractile stress fibers and of degradative enzymes, as well as the deposition of fibronectin and type I collagen were superior in microtissues with a low amount of CMs. Moreover, high CM-based microconstructs simulating a ratio similar to that of healthy tissues, even if subjected to both cyclic stretch and TGF-β1, did not show any of the investigated fibrotic signs, indicating a CM fibrosis modulating effect. Overall, this fibrosis model could help to uncover new pathological aspects studying, with mid-throughput and in a mechanically active, physiologically relevant environment, the crosstalk between the most abundant cell types involved in fibrosis.
心脏纤维化是心肌的一种适应性重塑,其特征为收缩功能受损和细胞外基质(ECM)过度沉积。然而,疾病进展仍知之甚少,目前的治疗方法无法控制瘢痕形成过程。部分原因是缺乏生理相关、易于操作且成本低廉的模型,而这些模型对于揭示病理机制和突出抗纤维化治疗的可能靶点至关重要。在经典模型中,通常使用具有瘢痕模拟硬度的底物和/或添加形态发生素(如转化生长因子β1,TGF-β1)来获得纤维化特征。然而,诸如活化成纤维细胞(FBs)与心肌细胞(CMs)之间的相互作用,或机械活性三维(3D)环境等因素被忽视,或者是以牺牲可实现的实验重复次数为代价来获得。为克服这些缺点,我们设计了一种微生理系统(MPS),其中多个3D心脏微组织可同时进行周期性拉伸。单个装置中可包含多达六个不同的生物学独立样本,提高了实验通量,并为更高产量的药物筛选活动铺平了道路。新开发的MPS用于共培养不同比例的新生大鼠CMs和FBs,研究CMs在不添加形态发生素且在柔软底物中对纤维化特征调节的作用。收缩应激纤维和降解酶的表达,以及纤连蛋白和I型胶原的沉积在CMs含量低的微组织中更显著。此外,模拟与健康组织相似比例的高CMs微构建体,即使同时受到周期性拉伸和TGF-β1作用,也未显示出任何所研究的纤维化迹象,表明CMs具有纤维化调节作用。总体而言,这种纤维化模型有助于在中等通量且机械活性、生理相关的环境中研究参与纤维化的最丰富细胞类型之间的相互作用,从而揭示新的病理方面。